Core Laboratories N.V.
NYSE:CLBOil & Gas Equipment & Services
+$0.12 today
- Market cap
- $387.21M
- Beta
- 0.99
- P/E (TTM)
- 18.3
- EPS (TTM)
- $0.63
- Dividend yield
- 0.35%
Volume 0.52M
Average 0.49M
CLB EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Core Laboratories N.V.NYSE: CLB
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.02, compared with -$0 a year earlier. Trailing-twelve-month EPS (Diluted) was $0.65. Over 3 fiscal years it compounded at +17.4% a year.
Context
- EPS (Diluted) increased in 2 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 2 analysts of $0.47 (-30.8%) for the fiscal year ending Dec 2026, a slowdown from the +3.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.02-113.3% QoQ
- Last fiscal yearDec 2025
- $0.68+3.0% YoY
- LTMMar 2026
- $0.65+8.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -506.1% | -60.5% | +445.5 pp |
| 1 year | +3.0% | -30.8% | -33.8 pp |
| 3-year CAGR | +17.4% | +10.0% | -7.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- 0.68 USD
- Year-over-year change
- +3.0%
- 4-year CAGR
- +12.8%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0.68 | +3.0% |
| FY2024 | 2024-12-31 | 0.66 | -14.3% |
| FY2023 | 2023-12-31 | 0.77 | +83.3% |
| FY2022 | 2022-12-31 | 0.42 | +0.0% |
| FY2021 | 2021-12-31 | 0.42 | — |
EPS (Diluted) vs competitors
How CLB compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +8.9% is the 4th highest of 10, against a peer median of -118.3%.
- Over three fiscal years its annual growth of +17.4% compares with a peer median of -33.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $12.29 USD | +178.6% | — | |
| LTM Mar 2026 | $1.51 USD | +88.8% | -12.6% | |
| LTM Mar 2026 | $0.65 USD | +8.9% | +17.4% | |
| LTM Mar 2026 | $0.13 USD | -23.2% | — | |
| LTM Mar 2026 | -$0.25 USD | -367.7% | -55.0% | |
| LTM Mar 2026 | -$0.5 USD | -164.7% | +35.0% | |
| LTM Mar 2026 | -$1.19 USD | -230.3% | -59.3% | |
| LTM Mar 2026 | -CA$1.28 CAD | -118.3% | — | |
| LTM Mar 2026 | -$1.83 USD | -544.0% | — | |
| LTM Mar 2026 | -$4.41 USD | +47.1% | — | |
| Peer median (excluding CLB) | — | -118.3% | -33.8% | |
Competitors are the stored peer set for CLB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 470.25M | 489.74M | 509.79M | 523.85M | 526.52M |
| Cost of Revenue | 386.41M | 410.82M | 415.74M | 435.48M | 432.24M |
| Gross Profit | 83.84M | 78.92M | 94.05M | 88.37M | 94.28M |
| Gross Margin | 17.8% | 16.1% | 18.4% | 16.9% | 17.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 44.17M | 38.12M | 38.89M | 38.59M | 44.23M |
| Operating Expenses | 38.58M | 37.4M | 39.41M | 29.82M | 43.8M |
| Depreciation & Amortization | 18.52M | 17.16M | 15.78M | 14.95M | 14.65M |
| EBITDA | 63.78M | 58.69M | 70.42M | 73.51M | 71.12M |
| EBITDA Margin | 13.6% | 12.0% | 13.8% | 14.0% | 13.5% |
| Operating Income | 45.26M | 41.52M | 54.64M | 58.56M | 50.49M |
| Operating Margin | 9.6% | 8.5% | 10.7% | 11.2% | 9.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 9.15M | 11.57M | 13.43M | 12.37M | 10.57M |
| Other Income / Expenses | (9.15M) | (11.57M) | (13.43M) | (12.37M) | (4.59M) |
| Income Before Tax | 36.11M | 29.95M | 41.21M | 46.19M | 45.9M |
| Pre-Tax Margin | 7.7% | 6.1% | 8.1% | 8.8% | 8.7% |
| Income Tax Expense | 15.89M | 10.3M | 4.19M | 14.03M | 15.51M |
| Net Income | 19.73M | 19.45M | 36.68M | 31.4M | 29.67M |
| Net Margin | 4.2% | 4.0% | 7.2% | 6.0% | 5.6% |
| EPS (Basic) | 0.43 | 0.42 | 0.79 | 0.67 | 0.68 |
| EPS (Diluted) | 0.42 | 0.42 | 0.77 | 0.66 | 0.68 |
| Weighted Avg Shares | 46.01M | 46.33M | 46.68M | 46.9M | 46.5M |
| Weighted Avg Shares (Diluted) | 46.69M | 46.81M | 47.52M | 47.69M | 46.5M |
Core Laboratories N.V.
NYSE:CLB
Intrinsic Alpha fair value
Locked
Current Price
$8.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.